Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study.
We aimed to estimate the total health care costs attributable to prostate cancer (PCa) during care phases by age, cancer stage, tumor grade, and primary treatment in the first year in British Columbia (BC), Canada. Using linked administrative health data, we followed a cohort of men aged ≥ 50 years...
| Publicado en: | Current Oncology Vol. 30; no. 3; pp. 3176 - 3189 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Mar2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=162747207&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 162747207 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Mar2023 vid: 30 iid: 3 pid: 97109 pub: MDPI artinfo: ui: 162747207 10.3390/curroncol30030240 162747207 ppf: 3176 ppct: 13 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study. aug: au: Zhang, Wei Guh, Daphne P. Mohammadi, Tima Pataky, Reka E. Tam, Alexander C. T. Lynd, Larry D. Conklin, Annalijn I. affil: Centre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada sug: ab: We aimed to estimate the total health care costs attributable to prostate cancer (PCa) during care phases by age, cancer stage, tumor grade, and primary treatment in the first year in British Columbia (BC), Canada. Using linked administrative health data, we followed a cohort of men aged ≥ 50 years at diagnosis with PCa between 2010 and 2017 (Cohort 1) from the diagnosis date until the date of death, the last date of observation, or 31 December 2019. Patients who died from PCa after 1 January 2010, were selected for Cohort 2. PCa attributable costs were estimated by comparing costs in patients to matched controls. Cohort 1 (n = 22,672) had a mean age of 69.9 years (SD = 8.9) and a median follow-up time of 5.2 years. Cohort 2 included 6942 patients. Mean PCa attributable costs were the highest during the first year after diagnosis ($14,307.9 [95% CI: $13,970.0, $14,645.8]) and the year before death ($9959.7 [$8738.8, $11,181.0]). Primary treatment with radiation therapy had significantly higher costs each year after diagnosis than a radical prostatectomy or other surgeries in advanced-stage PCa. Androgen deprivation therapy (and/or chemotherapy) had the highest cost for high-grade and early-stage cancer during the three years after diagnosis. No treatment group had the lowest cost. Updated cost estimates could inform economic evaluations and decision-making. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|